Merck will review the FDAs letter and feedback to determine the next steps for gefapixant, according to Wednesdays announcement of the CRL

States mentioned other varied Medicaid program priorities, in addition to navigating state budget challenges and implementing H.R.1 provisions , including: expanding access , especially behavioral health and long-term care, often through payment rate reviews and reimbursement reform implementing initiatives that target specific populations , including pregnant individuals, justice-involved, and people experiencing or at risk of homelessness continuing delivery systems efforts , including strengthening managed care performance and oversight and implementing value-based payment models improving administrative systems / functions , including large-scale efforts to modernize IT infrastructure and expanding program integrity efforts Methods KFF commissioned Health Management Associates (HMA) to survey Medicaid directors in all 50 states and the District of Columbia to identify and track trends in Medicaid spending, enrollment, and policy making

Mar 05, 2025, 08:00 ET NovoCare Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients While 90% of patients taking Wegovy have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverage Amidst the dangers of fake or illegitimate compounded "semaglutide," NovoCare Pharmacy offers reliable access to authentic, FDA-approved Wegovy in our once-weekly, single-dose pen PLAINSBORO, N.J., March 5, 2025 /PRNewswire/ -- As part of its ongoing efforts to ensure patients who need Wegovy (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access it, Novo Nordisk launched NovoCare Pharmacy, a direct-to-patient delivery option that offers cash-paying patients all dose strengths of Wegovy at a reduced cost of $499 per month
Gao, X.-J